AstraZeneca suffers diabetes drug setback for #Covid19

───   06:23 Tue, 13 Apr 2021

AstraZeneca suffers diabetes drug setback for #Covid19 | News Article

British pharmaceutical giant AstraZeneca said that following a trial, its diabetes drug Farxiga was not successful in treating COVID-19 patients at risk of severe complications.

AstraZeneca, whose separate COVID-19 vaccine rollout has been hampered by health concerns, said its trial "assessing the potential of Farxiga to treat patients hospitalised with COVID-19, who are at risk of developing serious complications... did not achieve statistical significance".

The trial was carried out alongside Saint Luke's Mid America Heart Institute and looked at potential complications including diabetes and heart failure.

"While the trial did not achieve statistical significance, the findings are very interesting and valuable, and will inform future clinical science," Saint Luke's cardiologist Mikhail Kosiborod said in a joint statement.

Public confidence in AstraZeneca's COVID-19 vaccine has meanwhile been badly shaken by reports linking it to rare, but potentially fatal, blood clots, and by conflicting recommendations over its use.


@ 2021 OFM - All rights reserved Disclaimer | Privacy Policy | We Use Cookies - OFM is a division of Central Media Group (PTY) LTD.

  Visit the official Covid-19 Portal  More Information
Visit the official Covid-19 Portal
Cookies help us deliver our services. By using our site, you agree to our use of cookies. Tell me more